Early-stage Funding VentriFlo is in the development stage with a recent $10M Series A and FDA submission activity, signaling willingness to engage with strategic partners, contract manufacturers, and clinical trial collaborators to accelerate regulatory milestones and product readiness.

Strategic Health-Tech Fit The true pulsatile pump targets pediatric and adult CPB and pulsatile VA ECMO use, suggesting opportunities with hospital systems, surgical centers, pediatric centers, and ECMO programs seeking innovative circulatory support solutions.

Regulatory Milestones With ongoing FDA 510(k) submission efforts, potential buyers and partners will look for risk-sharing arrangements, clinical validation collaborations, and early access programs to de-risk adoption timelines.

Tech & Integration Current tech stack and cloud-based operations indicate readiness to partner with compliant manufacturers and integration teams, enabling joint development, data interoperability, and scalable manufacturing collaborations.

Market Positioning Small to mid-market focus with a niche product offering creates a pathway for strategic alliance with larger medical device players, contract manufacturers, and distribution partners seeking differentiation in pediatric and critical care devices.